4 principles for the future of pharma marketing
AstraZeneca sells rights to cholesterol drug Crestor to Grunenthal
How COVID-19 is changing the sales model
Mundipharma, Grünenthal accused of kickbacks in Italy
Grünenthal buys certain rights to AZ’s Nexium and Vimovo for $922m
Ironwood tears up licensing agreement after sales disappoint
AZ considers options as US gout drug deal backfires
AZ says migraine outside its strategic focus.
AZ sells migraine drug rights to Grunenthal for $300m
Companies’ actions discredited the industry, says PMCPA.
Five UK pharma companies “named and shamed” by watchdog